What you need to know about AI medical coding and GLP-1 microdosing – statnews.com
What you need to know about AI medical coding and GLP-1 microdosing statnews.com
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo
HOUSTON–(BUSINESS WIRE)–Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, today announced results of an in vivo animal study designed to evaluate the effects of COYA 303 (LD IL-2 and GLP-1RA investigational proprietary biologic combination) in a well-characterized in vivo lipopolysaccharide […]
Novo Roundtrips GLP-1 Craze Ahead Of Earnings As Goldman Maps Out Next Wave Of Obesity-Drug Catalysts
Novo Roundtrips GLP-1 Craze Ahead Of Earnings As Goldman Maps Out Next Wave Of Obesity-Drug Catalysts The rollercoaster ride of the GLP-1 craze and bust cycle for Novo Nordisk A/S shares has been wild to observe over the last several years. The stock has since returned to roughly pre-GLP-1-boom levels, down 50% year-to-date amid intensifying obesity-drug competition […]
Is Eli Lilly a Millionaire Maker?
Key Points Eli Lilly’s GLP-1 drug portfolio should power the business for at least the next decade. But the market appears well aware of the company’s weight loss drug success. Weight loss drugs are set to become a disproportionate share of Lilly’s business. 10 stocks we like better than Eli Lilly › Pharmaceutical maker Eli […]
Here’s What Weighed on Eli Lilly and Company’s (LLY) Performance
Baron Funds, an investment management company, released its “Baron Health Care Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund rose 5.39% (Institutional Shares) in the quarter, compared to a 5.05% gain for the Russell 3000 Health Care Index (benchmark) and an 8.18% gain for the Russell 3000 […]
Phenomix Sciences Expands Evidence for MyPhenome™ Test Predicting GLP-1 Response and Obesity Risk in Large, Diverse Populations
Studies presented at Obesity Week 2025 validate the test’s ability to predict weight-loss response to GLP-1 drugs like semaglutide, including in diverse patient populations and post-bariatric surgery patients. Phenomix’s MyPhenome test continues to demonstrate predictive accuracy in…
Nestlé bets on start-ups for GLP-1 innovation
Nestlé is embracing the GLP-1 revolution with new weight management innovations, academic partnerships, and products tailored to users of drugs like Wegovy and Ozempic. Discover how the food industry is responding to changing consumer needs in the GLP-1 era.
STAT+: Microdosing aims to extend the lifespan of the GLP-1 compounding market
Noom, Found, and Hims & Hers have all launched programs to prescribe “microdosed” GLP-1s in the last three months, following in the footsteps of many smaller direct-to-consumer telehealth companies. Microdosing is getting a shot of promotion from Hollywood, too: Noom has promoted its program alongside a new celebrity spokesperson, actor Rebel Wilson, and TV host […]
Searching ‘weight’ can bring up Ozempic in results. It’s a drug advertising loophole
There are strict rules about what drug companies can say in TV or print ads. But a new study shows there’s a lot more wiggle room when companies pay to sponsor online search results.
Pharmacological intervention: Challenges and promising outcomes for fat loss and preservation of lean body mass in the treatment of overweight and type 2 diabetes
Abstract Treatment with GLP-1 receptor agonists (GLP-1 RAs) is effective in reducing body weight in individuals with overweight and type 2 diabetes (T2D). However, measurements indicate that a considerable portion of the weight loss derives from fat-free mass (FFM), including skeletal muscle, which may compromise metabolic health and physical function. We aimed to evaluate the […]